Back to search results

Nicotinamide Riboside for Gulf War Illness

This study is testing whether a dietary supplement called Nicotinamide Riboside (NR) can increase levels of NAD+ in the blood of people with Gulf War Illness (GWI). NAD+ is a natural substance in your body important for energy. Researchers believe that people with GWI might have lower NAD+ levels. You can join if you are between 47 and 70 years old, male or female, and are generally healthy. The study aims to enroll 52 participants and is currently unclear about its recruitment status. The main goal is to see if NR can raise NAD+ levels in your blood after 10 weeks.

Study design
This is a randomized, double-blind, placebo-controlled study, meaning participants will be randomly assigned to receive either Nicotinamide Riboside or a look-alike placebo, and neither you nor the study staff will know which you are receiving. The study plans to include 52 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, changes in plasma NAD+ levels, will be measured at 10 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05243290

Nicotinamide Riboside Clinical Trial for GWI

Recruiting
NAAges 47–70InterventionalSupportive care
Roskamp Institute Inc.
~52 participants
Updated 2025-07-24 on ClinicalTrials.gov
What's tested:Nicotinamide RibosidePlacebo

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Changes in plasma NAD+ levels
Measured over 10 weeks

Conditions

Gulf War Illness

Explore related trials

Gulf war syndrome

NCT05243290

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Nova Southeastern University

    Fort Lauderdale, Floridastudy coordinator listed

    Recruiting

  • The Roskamp Institute

    Sarasota, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Laila Abdullah, PhD · PRINCIPAL_INVESTIGATOR · The Roskamp Institute
  • Michael Hoffmann, MD · PRINCIPAL_INVESTIGATOR · The Roskamp Institute
  • Nancy Klimas, MD · PRINCIPAL_INVESTIGATOR · Nova Southeastern University
  • Amanpreet Cheema, PhD · PRINCIPAL_INVESTIGATOR · Nova Southeastern University

Who to contact

Dakota Helgager
[email protected]
9412568019 · ext. 3008
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Both sexes, all ethnic groups, and ages 47 to 70 years.
Subject willing and able to give informed consent.
Medically stable as per the investigator's discretion.
Negative urine pregnancy test for females of childbearing potential. A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is postmenopausal (no menstrual cycle for 2 years or more).
If female of childbearing potential, must be willing to use adequate birth control during the study and for 30 days after the last dose. Females agreeing to take an acceptable form of birth control per investigator discretion (where relevant). Females must prevent pregnancy or otherwise be unable to conceive.
Veterans deployed to the Gulf War between August 1990 and August 1991.
Veteran meets criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.
Weight of 50.0kg - 200.0kg (110 lbs. - 440 lbs.).

Exclusion

Diagnosed by a physician with medical or psychiatric conditions that would account for their symptoms or interfere with their ability to report their symptoms, as per investigator discretion.
Female subject is either pregnant or nursing; or if female subject is of childbearing age is not currently on or is unwilling and/or unable to use birth control.
Have contraindications, allergy, or sensitivity to NR, vitamin B3, or excipients (microcrystalline cellulose, silicon dioxide, magnesium stearate, hypromellose, and/or titanium dioxide).
Any significant medical condition that could interfere with study conduct, as per investigator discretion. These may include but are not limited to the following: untreated chronic hypertension (defined as systolic \> 180 mmHg; diastolic \>110 mmHg), myocardial infarction within 6 months of screening, renal failure, hepatic failure, and/or receiving chemotherapy.
Clinically significant lab values for clinical laboratory assessments, as per investigator discretion.
Poor venous access.
Current use of any NR supplement products (such as nicotinamide, nicotinamide mononucleotide (NMN), vitamin B3/Niacin, vitamin B complex, etc.) within 30 days of screening.
Participation in another clinical trial involving dietary or pharmaceutical intervention within 90 days of screening.

What this trial measures

  • Changes in plasma NAD+ levels10 weeks

    The primary objective is to determine if NR can increase plasma NAD+ levels in GWI veterans.